June 13, 2023 11:02 AM EDT
News Briefing

Seagen touts PhII da­ta for Ad­cetris/Op­di­vo com­bo; A-Al­pha part­ners with Gilead on HIV

Tyler Patchen

News Reporter

Seagen has re­vealed the da­ta from Part C of a Phase II tri­al eval­u­at­ing Ad­cetris in com­bi­na­tion with Op­di­vo (nivolum­ab), a PD-1 in­hibitor, as well …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times